orasur technolog inc specimen
collect vitro diagnost compani
primarili engag develop
manufactur market sale collect
devic proprietari oral fluid technolog
requir disclosur end report
consum genom fire ceo chang matter
littl us up pt reiter buy
view current cl king meet event calendar coverag univers
last week san francisco met orasur outgo ceo doug
michel incom ceo dr stephen tang recent trend consum
genom keep us interest orasur stori think ceo shift
derail compani fulli execut trend thesi
osur exposur blossom consum genom market make
incred asset overal think signific upsid
consum genom number revenu especi ep
perspect reiter buy rate rais price target
thought meet goal meet mr michel tri
understand anyth fundament wrong busi
might facilit chang manag although continu
cautiou oversea infecti diseas busi overal reiter
confid molecular collect great growth busi
infecti diseas would repres upsid opinion fundament
whether orasur differ manag
model updat model reflect orasur recent beat multi-year
deal increas revenu number
respect model ep
respect note
dna genotek good busi earn perspect see
upsid earn number remind benefit
transit mr michel still answer question dr
tang mostli observ dont mind dr tang quiet approach settl
role didnt get sens orasur look even need
clear deck frankli busi perform well enough
cfo ron spair orasur look new cfo immedi
although current cfo ron spair give compani flexibl find
suitabl replac recal mr spair hold titl cfo
replac take cfo role role
consolid dr tang role
acquisit mr michel confid dr tang
perspect happi learn type busi orasur
look acquir includ sampl prep technolog even librari prep
synergi collect stabil dna readi dna
becom testabl product obviou us addit ad technolog
valu chain could help compani creat addit barrier
infecti diseas mr tang say like dna genotek
infecti diseas segment although obvious happi growth
dna genotek less depend contract government/non-
profit payor infecti diseas busi littl pipelin beyond
test ebola zika wouldnt surpris orasur announc new
product segment make acquisit area
dna genotek ilmna announc seven
million consum test perform less
three million last year ancestri com see explos growth
could repres upsid orasur revenu number illumina
subsidiari helix also area invest
comp tough year comp assum
pre-announce final number dna genotek grew revenu well
orasur countrywid elimin deal think
egypt headwind think valuat
perspect think true growth rate project
growth rate
orasur project revenu least significantli higher
guidanc compar
compani expect molecular collect alon orasur make
four-year plan reevalu everi two year next plan reevalu
occur summer weve spoken manag past
talk time alloc split infecti diseas segment
dna genotek tini remaind dedic small
busi drug test cryo suspect next
meet orasur could shift even toward dna genotek
stephen tang mr michel spoke highli dr tang first word
use describ highli strateg thinker januari
januari dr tang serv presid chief execut offic
univers citi scienc center urban research park busi
incub own lead univers medic school health
network prior posit dr tang work gener manag
life scienc group olympu america
ceo millennium cell dr tang degre
colleg mari chemistri ph chemic
engin lehigh univers wharton
reiter buy rate rais price target
base ev/sal multipl revenu
risk achiev price target
depend contract
demand diseas erad effort
page
rapport lead health organ govern agenc
relationship supplier distribut partner
page
